Donanemab - Alzheimers disease
You are here : Home > Formulary Search > Donanemab - Alzheimers disease
Documentation
- No records returned.
PAD Profile
This drug has not yet been assessed for formulary status.
If a patient is accessing non-NHS supplies of this medication, refer to the NHSE information here (for a similar drug called lecanemab) which provides advice on potential adverse effects.
Committee Recommendations (1)
This drug has not yet been assessed for formulary status.
If a patient is accessing non-NHS supplies of this medication, refer to the NHSE information here (for a similar drug called lecanemab) which provides advice for clinical teams who may be asked to support referrals for private treatment or otherwise assess, advise and possibly treat a small number of patients who could present with potential adverse treatment effects, including symptomatic Amyloid-Related Imaging Abnormalities (ARIA).
This drug not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.
NICE are due to publish guidance on this drug in March 2025 and this will be considered by the APC within 90 days of publication.
Other Indications
Below are listed other indications that Donanemab is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Alzheimers disease.